Category: clinical study retractions

Ethical concerns arise for head of controversial stem cell clinic

Geeta Shroff. Photo credit: Nutech Mediworld

Journals are raising ethical concerns about the research of a doctor who offers controversial embryonic stem cell treatments.

Two journals have issued expressions of concern for three papers by Geeta Shroff, who was the subject of a 2012 CNN investigative documentary. All cite ethical concerns; one mentions the potential link between the procedure the authors describe and a risk of forming teratomas, a type of tumor. Shroff has objected to all three notices.

Shroff, a doctor offering controversial embryonic stem cell treatments at her New Delhi clinic, Nutech Mediworld, has said that for years she couldn’t find opportunities to present her research to the medical community. Continue reading Ethical concerns arise for head of controversial stem cell clinic

Caught Our Notice: Another retraction for researcher paid $100k to leave uni

Via Wikimedia

When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year.  And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of 1,000 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at [email protected].

Title:  Diabetes and Overexpression of proNGF Cause Retinal Neurodegeneration via Activation of RhoA Pathway  and  Diabetes-Induced Superoxide Anion and Breakdown of the Blood-Retinal Barrier: Role of the VEGF/uPAR Pathway 

What caught our attention:

Continue reading Caught Our Notice: Another retraction for researcher paid $100k to leave uni

Journal: Publish here, and we’ll pay you $500

A new journal is offering something we’ve never seen before: A cash reward to corresponding authors of papers it publishes.

Normally, in the case of open-access journals, researchers have to pay article processing charges (APCs). But Minimally Invasive Surgical Oncology, an open-access journal launched at the end of last year, flips the typical narrative — it will pay corresponding authors $500 for every original or review article it accepts. If any author joins the editorial board, the payment — which the journal dubs “royalties” — increases to $600.

Editor Wenyuan Chen admitted it’s an unusual policy:

Continue reading Journal: Publish here, and we’ll pay you $500

Boys will be boys: Data error prompts U-turn on study of sex differences in school

The authors of a 2017 paper on emotional and behavioral gaps between boys and girls have retracted the article after discovering a coding error that completely undermined their conclusions.

The revelation prompted the researchers to republish their findings in the same journal, this time with a title that flips the narrative.

The PsychJournal study, first published in March, looked at self-regulation — loosely defined as the ability to get stuff done and keep a lid on it —  in boys and girls in German elementary schools. Although previous studies had found girls might do better on this front, the authors, from the University of Leipzig and New York University’s Abu Dhabi campus, initially found the opposite:

Continue reading Boys will be boys: Data error prompts U-turn on study of sex differences in school

Are rich people meaner? While trying to find out, two teams find errors in each other’s work

Is having money linked to bad behavior?

A high profile paper published in 2012 in the Proceedings of the National Academy of Sciences (PNAS) set out to answer that question — and found that yes, the more money people have, the more likely they are to lie, cheat, and steal. And the greedier they are, the worse they behave. But when a more recent paper tried to replicate some of those findings, it couldn’t.

It turns out, both the original paper and the paper that tried to replicate it contained errors. Although neither appear to affect the main conclusions, the authors of the 2016 replication recently issued a correction; the error in the 2012 paper was initially deemed too insignificant to correct, but the journal has decided to revisit the idea of issuing a correction.

A representative of PNAS told us that the replication paper — and reporting by Retraction Watch — is the reason why: Continue reading Are rich people meaner? While trying to find out, two teams find errors in each other’s work

Dispute over author order torpedoes paper on syndrome linked to autism

At least one disgruntled co-author has triggered the retraction of a paper presenting a novel approach to treating a rare, genetically inherited condition.

The paper concerned research on Fragile X syndrome (FXS), characterized by both intellectual and physical abnormalities, which is linked autism. A compound that passed through phase 2 clinical trials in October 2015 appeared to partially treat FXS in mice in the study, published earlier this year.

The journal’s notice says the paper was retracted over a dispute among authors about the order in which they are listed on the paper: Continue reading Dispute over author order torpedoes paper on syndrome linked to autism

Journal issues note of concern, tips off university’s research integrity office

A journal has published an expression of concern (EoC) for a paper on cancer genetics in mice, over a concern about data in some gel panels.

The EoC for “Suppression of intestinal tumorigenesis in Apc mutant mice upon Musashi-1 deletion,” appeared Sept. 21 in Journal of Cell Science (JCS).

With the notice, the journal says:

Continue reading Journal issues note of concern, tips off university’s research integrity office

Journal to retract paper called “anti-vaccine pseudoscience”

A journal is planning to retract a paper that purported to link a component of vaccines to autism in mice.

The paper, about the effects of aluminum adjuvants in vaccines on the immune response in the brains of mice, is the second retraction for co-authors Christopher Shaw and Lucija Tomljenovic, of the University of British Columbia. The journal’s editor told us he and the authors are jointly retracting the paper. 

Just over a month old, the paper has already received plenty of criticism. Numerous commenters on PubPeer have allegedly identified image duplications and other problems with the paper. One commenter described “clear and deliberate” removal of control results in the paper, while others suggested gel bands were duplicated within the paper, and appear similar to those from another paper published in 2014 by Shaw and Tomljenovic. In a blog post, David Gorski, a professor and surgeon at Wayne State University, called the paper “antivaccine pseudoscience.”

Shaw, the paper’s last author, told us that his lab became aware of the PubPeer discussion a few weeks after publication:  Continue reading Journal to retract paper called “anti-vaccine pseudoscience”

Society recommends 9 retractions for co-author of researcher with record number of retractions

The Japanese Society of Anesthesiologists (JSA) has requested the retraction of nine additional papers by a co-author of fraudster Yoshitaka Fujii, after investigating allegations of fraud in dozens of papers.

According to the report, a committee investigated approximately 40 publications by Yuhji Saitoh of Yachiyo Medical Center and Tokyo Women’s Medical University and “identified ten publications with clear ethics violations, one of which has already been retracted.”

Saitoh has collaborated on many papers with Fujii, an anesthesia researcher with more than 180 retractions. As we reported, Saitoh resigned from the JSA when the investigation began, and the society permanently banned him. Continue reading Society recommends 9 retractions for co-author of researcher with record number of retractions

Early data on potential anti-cancer compound now in human trials was falsified, company admits

A pharmaceutical company has admitted that one of its former researchers falsified early data on a compound that’s designed to fight cancer, now in human trials.

The data, published as an abstract in August 2015 in the journal Cancer Research, reported a therapeutic benefit of acalabrutinib in a mouse model of pancreatic cancer. The compound, developed by the company Acerta Pharma, has also been the subject of additional trials published in the New England Journal of Medicine and Blood in 2015. The 2015 NEJM study, which had several authors in common with the Cancer Research abstract, showed the agent had “promising safety and efficacy profiles in patients” with relapsed chronic lymphocytic leukemia.

But an investigation into the data underlying the 2015 abstract shows some were falsified, prompting the journal to retract the abstract.

Ed Tucker, senior vice president of Medical Safety, Quality and Compliance at Acerta Pharma, told us that in August 2016 the company identified an issue with the data in the Cancer Research abstract and started an investigation:

Continue reading Early data on potential anti-cancer compound now in human trials was falsified, company admits